Literature DB >> 18219364

The emergence of peptides as therapeutic drugs for the inhibition of HIV-1.

Alexandra Huther1, Ursula Dietrich.   

Abstract

Due to their small size and specific binding properties, peptides are very suited to interfere with protein-protein interactions and thus are ideal drug candidates aiming at such targets in the complex cellular interactome. Peptides can easily be selected from natural or artificial peptide libraries for any target and further optimized by in silico analysis, chemical synthesis, and the introduction of non-natural amino acids. Here we review the current status of peptide drugs with special emphasis on the inhibition of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18219364

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  10 in total

Review 1.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

2.  Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs.

Authors:  Leonard T Nguyen; Johnny K Chau; Nicole A Perry; Leonie de Boer; Sebastian A J Zaat; Hans J Vogel
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

3.  Natural antimicrobial peptides as promising anti-HIV candidates.

Authors:  Guangshun Wang
Journal:  Curr Top Pept Protein Res       Date:  2012

4.  PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues.

Authors:  Sandeep Singh; Harinder Singh; Abhishek Tuknait; Kumardeep Chaudhary; Balvinder Singh; S Kumaran; Gajendra P S Raghava
Journal:  Biol Direct       Date:  2015-12-21       Impact factor: 4.540

5.  Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.

Authors:  Steven Samuels; Zainab Alwan; Marceline Egnin; Jessie Jaynes; Terry D Connell; Gregory C Bernard; Toufic Nashar
Journal:  J AIDS Clin Res       Date:  2017-10-23

6.  Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles.

Authors:  Zheyong Huang; Yanan Song; Zhiqing Pang; Bo Zhang; Hongbo Yang; Hongtao Shi; Jing Chen; Hui Gong; Juying Qian; Junbo Ge
Journal:  Int J Nanomedicine       Date:  2017-04-12

7.  HIPdb: a database of experimentally validated HIV inhibiting peptides.

Authors:  Abid Qureshi; Nishant Thakur; Manoj Kumar
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

8.  Designing cyclopentapeptide inhibitor as potential antiviral drug for dengue virus ns5 methyltransferase.

Authors:  Syarifuddin Idrus; Usman Sumo Friend Tambunan; Ahmad Ardilla Zubaidi
Journal:  Bioinformation       Date:  2012-04-30

9.  Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1.

Authors:  Chee Wah Tan; Yoke Fun Chan; Kooi Mow Sim; Eng Lee Tan; Chit Laa Poh
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

10.  Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.

Authors:  Luciano Polonelli; José Pontón; Natalia Elguezabal; María Dolores Moragues; Claudio Casoli; Elisabetta Pilotti; Paola Ronzi; Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Domenico Leonardo Maffei; Walter Magliani; Stefania Conti; Luiz R Travassos
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.